Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 143

1.

The effects of exenatide bid on metabolic control, medication use and hospitalization in patients with type 2 diabetes mellitus in clinical practice: a systematic review.

Best JH, Lavillotti K, DeYoung MB, Garrison LP.

Diabetes Obes Metab. 2012 May;14(5):387-98. doi: 10.1111/j.1463-1326.2011.01533.x. Epub 2011 Dec 27. Review.

PMID:
22074017
2.

Use of concomitant glucose-lowering therapies and associated treatment results observed in clinical trials of twice-daily exenatide.

Pencek R, Brunell SC, Li Y, Hoogwerf BJ, Malone J.

Endocr Pract. 2012 Mar-Apr;18(2):227-37. doi: 10.4158/EP11306.OR.

PMID:
22446132
3.

Clinical outcomes of concomitant therapy of exenatide twice daily and basal insulin in patients with type 2 diabetes mellitus: a retrospective database analysis in the United States.

Pawaskar M, Li Q, Hoogwerf BJ, Reynolds MW, Lee LJ, Fonseca V.

Endocr Pract. 2012 Sep-Oct;18(5):700-11. doi: 10.4158/EP11367.OR.

PMID:
22982784
4.

Metabolic outcomes of matched patient populations initiating exenatide BID vs. insulin glargine in an ambulatory care setting.

Pawaskar M, Li Q, Hoogwerf BJ, Reynolds MW, Faries D, Engelman W, Bruhn D, Bergenstal RM.

Diabetes Obes Metab. 2012 Jul;14(7):626-33. doi: 10.1111/j.1463-1326.2012.01581.x. Epub 2012 Mar 8.

PMID:
22321776
5.

Addition of thiazolidinedione or exenatide to oral agents in type 2 diabetes: a meta-analysis.

Pinelli NR, Cha R, Brown MB, Jaber LA.

Ann Pharmacother. 2008 Nov;42(11):1541-51. doi: 10.1345/aph.1L198. Epub 2008 Oct 28.

PMID:
18957626
6.

Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study.

Moretto TJ, Milton DR, Ridge TD, Macconell LA, Okerson T, Wolka AM, Brodows RG.

Clin Ther. 2008 Aug;30(8):1448-60. doi: 10.1016/j.clinthera.2008.08.006. Erratum in: Clin Ther. 2008 Oct;30(10):1937.

PMID:
18803987
7.

Clinical outcomes using long-term combination therapy with insulin glargine and exenatide in patients with type 2 diabetes mellitus.

Levin PA, Mersey JH, Zhou S, Bromberger LA.

Endocr Pract. 2012 Jan-Feb;18(1):17-25. doi: 10.4158/EP11097.OR.

PMID:
21742605
8.

Exenatide added to insulin therapy: a retrospective review of clinical practice over two years in an academic endocrinology outpatient setting.

Yoon NM, Cavaghan MK, Brunelle RL, Roach P.

Clin Ther. 2009 Jul;31(7):1511-23. doi: 10.1016/j.clinthera.2009.07.021.

PMID:
19695400
9.

Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes.

Blonde L, Klein EJ, Han J, Zhang B, Mac SM, Poon TH, Taylor KL, Trautmann ME, Kim DD, Kendall DM.

Diabetes Obes Metab. 2006 Jul;8(4):436-47.

PMID:
16776751
12.

Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years.

Klonoff DC, Buse JB, Nielsen LL, Guan X, Bowlus CL, Holcombe JH, Wintle ME, Maggs DG.

Curr Med Res Opin. 2008 Jan;24(1):275-86.

PMID:
18053320
13.

Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus.

Ratner RE, Maggs D, Nielsen LL, Stonehouse AH, Poon T, Zhang B, Bicsak TA, Brodows RG, Kim DD.

Diabetes Obes Metab. 2006 Jul;8(4):419-28.

PMID:
16776749
14.

Exenatide: an incretin mimetic for the treatment of type 2 diabetes mellitus.

Iltz JL, Baker DE, Setter SM, Keith Campbell R.

Clin Ther. 2006 May;28(5):652-65. Review.

PMID:
16861088
15.
16.

Efficacy, safety, and tolerability of exenatide once weekly in patients with type 2 diabetes mellitus: an integrated analysis of the DURATION trials.

Grimm M, Han J, Weaver C, Griffin P, Schulteis CT, Dong H, Malloy J.

Postgrad Med. 2013 May;125(3):47-57. doi: 10.3810/pgm.2013.05.2660.

PMID:
23748506
17.

Exenatide: new drug. Type 2 diabetes for some overweight patients.

[No authors listed]

Prescrire Int. 2007 Dec;16(92):228-31.

PMID:
18087791
18.

Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes.

Kim D, MacConell L, Zhuang D, Kothare PA, Trautmann M, Fineman M, Taylor K.

Diabetes Care. 2007 Jun;30(6):1487-93. Epub 2007 Mar 12.

PMID:
17353504
19.

Exenatide once weekly for the treatment of type 2 diabetes mellitus: clinical results in subgroups of patients using different concomitant medications.

Pencek R, Brunell SC, Li Y, Hoogwerf BJ, Malone J.

Postgrad Med. 2012 Jul;124(4):33-40. doi: 10.3810/pgm.2012.07.2568.

PMID:
22913892
20.

Clinical implications of exenatide as a twice-daily or once-weekly therapy for type 2 diabetes.

Aroda VR, DeYoung MB.

Postgrad Med. 2011 Sep;123(5):228-38. doi: 10.3810/pgm.2011.09.2479. Review.

PMID:
21904106

Supplemental Content

Support Center